Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Portola Pharmaceuticals Inc. PTLA

Healthcare Biotechnology
"Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of... see more

Recent & Breaking News (NDAQ:PTLA)

NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: PORTOLA PHARMACEUTICALS, INC. (NASDAQ - PTLA), STEMLINE THERAPEUTICS, INC. (NASDAQ - STML) AND WILLIS TOWERS WATSON, PLC (NASDAQ - WLTW)

ACCESSWIRE IA May 8, 2020

Shareholder Alert: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA

ACCESSWIRE IA May 7, 2020

KLXE, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

GlobeNewswire May 7, 2020

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Portola Pharmaceuticals, Inc. - PTLA

PR Newswire May 6, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Portola Pharmaceuticals, Inc.

PR Newswire May 5, 2020

Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion

PR Newswire May 5, 2020

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.

PR Newswire May 5, 2020

Moore Kuehn Encourages TORC, STML, KLXE, and PTLA Investors to Contact Law Firm

PR Newswire May 5, 2020

PORTOLA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout

ACCESSWIRE IA May 5, 2020

Portola Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Sale Of Portola Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm

PR Newswire May 5, 2020

Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Portola Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Alexion Pharmaceuticals, Inc.

PR Newswire May 5, 2020

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire May 1, 2020

Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020

PR Newswire April 23, 2020

Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020

PR Newswire April 7, 2020

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire April 1, 2020

Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)

PR Newswire March 18, 2020

CLASS ACTION UPDATE for PTLA, GERN and CAN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

ACCESSWIRE IA March 16, 2020

PTLA DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Portola Pharmaceuticals Inc. Investors With Losses Exceeding $100K of Class Action and Lead Deadline: March 16, 2020

ACCESSWIRE IA March 16, 2020

Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds

PR Newswire March 16, 2020

SHAREHOLDER ALERT: PTLA BYND WBK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

ACCESSWIRE IA March 15, 2020